Benefits
Weight: a small and inconsistent effect
The weight evidence is small and inconsistent. A 2008 meta-analysis of 14 randomized trials (531 people) found a mean difference of 0.79 kg versus control, with a confidence interval running from 1.53 kg down to 0.05 kg, so the result sat close to zero. A 2014 meta-analysis restricted to overweight and obese participants (8 trials) found no significant difference at all: 0.22 kg, 95 percent CI from 0.62 kg lower to 0.19 kg higher. Two placebo-controlled trials were null. In 53 overweight adults, 4 g/day for 8 weeks changed neither weight, body composition, nor rated hunger and fullness. In 96 children and adolescents with overweight or obesity, 3 g/day for 12 weeks had no effect on BMI-for-age z score. The European Commission authorises a weight-loss claim at 3 g/day within an energy-restricted diet, but the fiber itself is worth at most a fraction of a kilogram, and it did not change body fat or BMI in these trials.
Cholesterol and LDL reduction
This is the best-supported effect. In a 2008 meta-analysis of 14 randomized trials, glucomannan lowered total cholesterol by 19.3 mg/dL and LDL cholesterol by 16.0 mg/dL versus control. An independent 2017 meta-analysis of 12 randomized trials (370 participants) found that about 3 g/day lowered LDL cholesterol by 0.35 mmol/L, roughly 10 percent, and non-HDL cholesterol by about 7 percent, with no measurable change in apolipoprotein B across the 6 trials that reported it. Three further meta-analyses published in 2023, 2024 and 2025 all agree that glucomannan lowers total and LDL cholesterol, and the 2025 one adds that the size of the change is not clinically important on its own and that glucomannan should be seen as an adjunct. The European Commission authorises the claim that 4 g/day contributes to maintaining normal blood cholesterol. This is a real and replicated change, but a modest one, and much smaller than what a statin produces. The mechanism involves bile acid sequestration, reduced intestinal cholesterol absorption, and increased hepatic LDL receptor expression from bile acid pool depletion.
Blood sugar: mixed results, studied mostly in type 2 diabetes
The glucose evidence is thinner and more mixed than the cholesterol evidence. The 2008 meta-analysis found fasting glucose 7.4 mg/dL lower than control across 14 trials, but the same analysis reported that people with impaired glucose metabolism did not benefit to the same degree as other groups. A 2023 meta-analysis of 6 randomized trials in 440 people already diagnosed with type 2 diabetes found lower fasting glucose, lower 2-hour post-meal glucose, lower fasting insulin and lower serum fructosamine; that result belongs to a treated patient population under medical care, not to a healthy person adding a fiber to their diet. In 11 adults with insulin resistance syndrome, 3 weeks of konjac-enriched biscuits lowered serum fructosamine by about 5 percent while fasting glucose, insulin and body weight were unchanged. In 53 overweight adults, 8 weeks of 4 g/day changed no glucose or lipid value. No meta-analysis has pooled an HbA1c result for glucomannan. Neither regulator recognises a blood-sugar claim for this fiber: the European Commission authorises glucomannan claims only for cholesterol and for weight loss, and the US FDA has authorised no health claim, qualified or otherwise, for glucomannan.
Prebiotic and gut health benefits
Glucomannan is fermented in the colon. In a diet-controlled study of 7 constipated adults, 1.5 g three times daily raised weekly bowel movements from 4.1 to 5.3, increased fecal lactobacilli and the daily output of bifidobacteria, raised fecal acetate and propionate, and lowered fecal pH. A meta-analysis of 3 randomized trials in 122 constipated children found about 1.4 extra bowel movements per week, but no significant change in stool consistency and no significant improvement in the proportion successfully treated. A 2025 double-blind randomized trial in male elite athletes with functional constipation reported better constipation symptom and quality-of-life scores alongside shifts in gut bacteria. Effects on colonic inflammation and gut barrier integrity have not been measured in people taking glucomannan.
Mechanism of action
Extreme gel viscosity and gastric emptying delay
Glucomannan absorbs up to about 50 times its weight in water and forms one of the most viscous gels produced by any dietary fiber, which is why doses of only 3 to 4 g/day are used. The gel raises the viscosity of gut contents and slows gastric emptying. The satiety step is inferred rather than shown: in the one placebo-controlled trial that actually rated hunger and fullness, 4 g/day for 8 weeks changed neither.
Bile acid sequestration and cholesterol reduction
The highly viscous glucomannan gel physically entraps bile acids in the small intestinal lumen, preventing their reabsorption into the enterohepatic circulation. The liver must convert additional cholesterol to bile acids to replace the excreted pool, reducing hepatic cholesterol and upregulating LDL receptors on hepatocytes — producing the consistent LDL reductions observed in clinical trials.
Gut hormone release: proposed, with no confirmed GLP-1 effect in people
Viscous fibers are proposed to increase release of the gut hormones GLP-1, PYY and CCK from enteroendocrine cells. For glucomannan this stays a proposal. Rodent studies report incretin and appetite-hormone changes, but no randomized placebo-controlled trial in people has shown that glucomannan raises GLP-1. The nearest human data come from an uncontrolled 12-week study of konjac foods in 26 people with type 2 diabetes, where GLP-1 only tended to rise and the change was not statistically significant (p = 0.071). A small 2009 study in type 2 diabetes did report lower ghrelin after a glucose load with glucomannan, a different hormone and a single small result.
Clinical trials
Systematic review and meta-analysis of 14 randomized controlled trials. Sood, Baker and Coleman, Am J Clin Nutr 2008;88(4):1167-75.
531 adults and children pooled from 14 randomized trials.
Glucomannan lowered body weight by 0.79 kg (95 percent CI 1.53 to 0.05 kg), total cholesterol by 19.3 mg/dL, LDL cholesterol by 16.0 mg/dL, triglycerides by 11.1 mg/dL and fasting glucose by 7.4 mg/dL versus control. HDL cholesterol and blood pressure did not change, and the authors reported that children, people already making dietary changes, and people with impaired glucose metabolism did not benefit to the same degree. The weight finding is fragile: a separate 2014 meta-analysis of 8 randomized trials in overweight and obese adults found no significant difference from placebo (0.22 kg, 95 percent CI 0.62 kg lower to 0.19 kg higher).
Systematic review and meta-analysis of 12 randomized controlled trials. Ho, Jovanovski, Vuksan and colleagues, Am J Clin Nutr 2017;105(5):1239-1247.
370 participants pooled from 12 randomized trials, 8 in adults and 4 in children.
About 3 g/day of konjac glucomannan lowered LDL cholesterol by 0.35 mmol/L, roughly 10 percent, and non-HDL cholesterol by about 7 percent versus control. Data from 6 of the trials showed no effect on apolipoprotein B. The proposed mechanism is bile acid binding by a viscous fiber, the same mechanism as oat beta-glucan and psyllium. The European Commission authorises a cholesterol claim for glucomannan at 4 g/day under Regulation (EU) No 432/2012; the US FDA does not list glucomannan among the soluble fibers eligible for its heart-disease health claim in 21 CFR 101.81. The cholesterol effect is the most consistent result for this fiber.